PIONERA will evaluate the efficacy and safety of giredestrant (oral SERD) compared with fulvestrant, both combined with the investigator’s choice of CDK4/6i in participants with ER+ and HER2− aBC who have developed resistance to adjuvant ET. The gene discussed is ESR1; the disease is aneurysmal bone cyst.